Cardiology Self-Assessment Program (CardSAP) (L259218)

The target audience for CardSAP 2025 is board-certified and advanced level cardiology clinical pharmacists.

Board-certified pharmacists are eligible to receive up to 20.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP are approved by BPS as a provider for the recertification of BCCP.

Chapter: Transthyretin-Related Amyloidosis
ACPE #: 0217-9999-25-225-H01-P

• Distinguish between the two main types of cardiac amyloidosis (CA)—monoclonal immunoglobulin light chain (AL) amyloidosis and transthyretin-related amyloidosis (ATTR)—and account for the differences in prognosis and treatment.
• Evaluate patients for the presentation of classic clinical features of CA, including cardiac and extracardiac manifestations.
• Apply features of a diagnostic algorithm to distinguish between different etiologies of CA, and correctly diagnose a patient with ATTR.
• Develop pharmacotherapy for a patient with ATTR cardiomyopathy (ATTR-CM) that addresses best supportive care, heart failure (HF) treatment, and other treatment of important comorbidities.
• Evaluate the appropriate use and place of therapy of emerging therapies for a patient with ATTR-CM.
• Assess the economic burden of the treatment of ATTR-CM disease-modifying therapies on both the patient and the health care system. 

Chapter: Iron Deficiency in Heart Failure
ACPE #: 0217-9999-25-226-H01-P

• Evaluate the rationale and recommendations for iron replacement in patients who have iron deficiency in heart failure (IDHF) with and without anemia.
• Assess the limitations of the current diagnostic criteria for IDHF.
• Distinguish the clinical evidence and differences in logistical considerations among available intravenous iron formulations.
• Design an appropriate intravenous iron replacement regimen for a patient with IDHF accounting for the challenges and practical considerations in both inpatient and outpatient settings.
• Investigate evidence for intravenous iron administration in understudied populations with HF and explore future directions. 

Chapter: Continuous-Flow Left Ventricular Assist Device
ACPE #: 0217-9999-25-227-H01-P

• Evaluate the role of guideline-directed medical therapy (GDMT) for myocardial recovery in patients with continuous-flow left ventricular assist device (CF-LVADs) according to recent guideline updates.
• Construct a pharmacotherapy plan for patients immediately before and after CF-LVAD implantation.
• Design an appropriate pharmacotherapeutic regimen in stable patients with CF-LVADs.
• Analyze available literature to determine the role of GDMT in the management of complications after CF-LVAD implantation. 

Chapter: Cardiac Sarcoidosis
ACPE #: 0217-9999-25-228-H01-P

• Apply knowledge of the pathophysiology of cardiac sarcoidosis (CS).
• Distinguish characteristics of patients with CS.
• Evaluate patients for the presence of diagnostic criteria for CS.
• Develop a treatment plan, including immunosuppression, rhythm control, and advanced therapies, for patients with CS.
• Assess the effect of clinical manifestations on clinical outcomes in a patient with CS. 

Chapter: Glucagon-Like Peptide-1 Receptor Agonists in CVD and HFpEF
ACPE #: 0217-9999-25-229-H01-P

• Analyze the pharmacology of incretin-based therapies and mechanisms of cardiovascular (CV) benefit.
• Evaluate published data to support the use of glucagon-like peptide-1 receptor antagonists (GLP-1 RAs) for CV risk reduction in patients with and at risk of CV disease.
• Distinguish medical, economic, and psychosocial barriers to GLP-1 RA prescribing.
• Design an appropriate workup for a patient presenting with heart failure with preserved ejection fraction (HFpEF).
• Develop an appropriate evidence-based regimen for the pharmacologic treatment of a patient with HFpEF. 

Chapter: Microvascular CVD/MINOCA/ANOCA
ACPE #: 0217-9999-25-230-H01-P

• Distinguish the differences in terminology and definitions between angina with nonobstructive coronary arteries (ANOCA) and myocardial infarction with nonobstructive coronary arteries (MINOCA) based on available guidelines and consensus statements.
• Demonstrate an understanding of the diagnostic modalities and testing results used for patients with suspected ANOCA.
• Design a treatment plan for patients with each of the currently identified endotypes of ANOCA.
• Apply appropriate steps necessary in the clinical evaluation of suspected MINOCA.
• Evaluate the current secondary prevention strategies in MINOCA and their expected effects on cardiovascular outcomes. 

Case Series: Mental Health and Pain Management in Patients with CVD
ACPE #: 0217-9999-25-231-H01-P

• Evaluate the complex interactions between mental health disorders, chronic pain, and cardiovascular disease and their impact on outcomes
• Design patient-centered, safe, and effective pharmacotherapy for managing mental health disorders and chronic pain in cardiovascular disease
• Integrate nonpharmacologic approaches as components of a comprehensive pain and mental health management plan tailored to patients with cardiovascular disease.
• Evaluate the role of palliative pharmacotherapy in end-stage cardiovascular disease to prioritize patient comfort and symptom relief. 

Case Series: Cardiovascular-Kidney-Metabolic Health
ACPE #: 0217-9999-25-232-H01-P

• Distinguish stages of the new cardiovascular-kidney-metabolic (CKM) syndrome.
• Evaluate the biological risk factors and social determinants of health contributing to the development of CKM syndrome.
• Evaluate a patient’s risk for cardiovascular disease (CVD) with the new PREVENT risk calculator.
• Given a patient case, devise a strategy to prevent the development or slow the progression of CKM syndrome.
• Develop treatment recommendations for the patient with CVD and CKM syndrome. 

Chapter: Artificial Intelligence in the Management of CVD
ACPE #: 0217-9999-25-233-H01-P

• Evaluate potential applications of artificial intelligence (AI) use in cardiovascular (CV) diseases.
• Apply contemporary AI/machine learning (ML) prediction models to patients receiving high-risk medications with CV implications.
• Design an AI-based remote monitoring plan for patients with CV diseases.
• Apply key concepts of phenomapping/clustering techniques to pharmacy practice.
• Demonstrate potential challenges of AI-based algorithms and prediction models.
• Justify potential clinical implications of AI in the future practice of CV pharmacists. 

Chapter: Statistics Applied to Heart Failure Studies: Win Ratio
ACPE #: 0217-9999-25-234-H01-P

• Distinguish the differences between the conventional approaches to analyzing heart failure (HF) trial outcomes and the win ratio (WR).
• Assess the differences in findings from HF trials reanalyzed using WR.
• Analyze the design and findings of contemporary HF trials using WR.
• Assess the strengths and weaknesses of WR use in HF trials and how clinicians should interpret and apply the findings.

Faculty Information

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

Consultancies: Lauren Kemp (Pfizer [two consultancies], Alnylam [two consultancies]); James C. Coons (AstraZeneca, Merck, Pfizer-Bristol Myers Squibb Alliance); Katherine E. Di Palo (Astra Zeneca, Pharmacosmos, American Regent, Faraday Pharmaceuticals); Lavinia Salama (Dexcom) 

Grants: Tomasz Jurga (American Heart Association); Erika M. Schoenborn (Campbell University); James C. Coons (Heart Rhythm Society); Katherine E. Di Palo (ACCP, PCORI, Astra Zeneca); Kazuhiko Kido (National Association of Chronic Disease Directors); William L. Baker (AstraZeneca); Catherine G. Derington (Amarin Pharma, Inc.) 

Honoraria: Amy Hathorn (UNC Charlotte CRNA Program); Lauren Kemp (BridgeBio) 

Royalties: Tomasz Jurga (Pharmacy Times/Merck & Co, Inc.) 

Stock: Dustin Spencer (Cardinal Health) 

ACCP Staff/Series Leaders

Consultancies: Cynthia Jackevicius (AHA, CSHP)

Grants: Cynthia Jackevicius (Heart and Stroke Foundation of Canada)

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ACCP and ASHP collaborate on cardiology pharmacy activities.